Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.
2.

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

Kessler DA.

J Am Podiatr Med Assoc. 1994 Jan;84(1):35-8. No abstract available.

PMID:
8295131
3.

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

Kessler DA.

Gen Hosp Psychiatry. 1994 Mar;16(2):96-101; discussion 102. No abstract available.

PMID:
8039699
4.

MedWatch. On lookout for medical product problems.

Ropp KL.

FDA Consum. 1993 Nov;27(9):14-7. No abstract available.

PMID:
10130376
5.

MEDWatch: the new FDA medical products reporting program.

Kessler DA.

Am J Hosp Pharm. 1993 Jun;50(6):1151-2. No abstract available.

PMID:
8517452
6.

MedWatch program.

White GG.

Int J Trauma Nurs. 1998 Jul-Sep;4(3):100-3. No abstract available.

PMID:
9855977
7.

Watching out for public safety.

Laskin DM.

J Oral Maxillofac Surg. 1993 Sep;51(9):959. No abstract available.

PMID:
8355100
8.

Postmarketing follow-up: physicians have key role.

Goldsmith MF.

JAMA. 1985 Oct 25;254(16):2217. No abstract available.

PMID:
4046146
9.

Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.

Landow L.

Reg Anesth Pain Med. 1998 Nov-Dec;23(6 Suppl 2):190-3. No abstract available.

PMID:
9845393
10.

Evaluating the completeness and accuracy of MedWatch data.

Getz KA, Stergiopoulos S, Kaitin KI.

Am J Ther. 2014 Nov-Dec;21(6):442-6. doi: 10.1097/MJT.0b013e318262316f.

PMID:
23011177
11.

MedWatch targets reporting of serious adverse events.

VanAmringe M.

Jt Comm Perspect. 1993 Jul-Aug;13(4):15. No abstract available.

PMID:
10129237
12.

Postmarketing surveillance: beyond MEDWatch.

Faich GA.

JAMA. 1993 Nov 10;270(18):2180. No abstract available.

PMID:
8411596
13.

MedWatch: the new medical products reporting program.

Couig MP, Merkatz RB.

Am J Nurs. 1993 Aug;93(8):65-8. No abstract available.

PMID:
8256839
14.

The prescription drug user fee act: active postmarketing drug surveillance and safety.

Lyles A.

Clin Ther. 2002 May;24(5):800-2. No abstract available.

PMID:
12075947
15.

MedWatch: the FDA medical products reporting program.

Rheinstein PH.

Am Fam Physician. 1993 Sep 15;48(4):636-8. No abstract available.

PMID:
8379493
16.

Food and Drug Administration update. The MedWatch program.

White GG, Love L.

J Toxicol Clin Toxicol. 1998;36(1-2):145-9. No abstract available.

PMID:
9541064
17.

Monitoring drug product quality.

Bolger G, Goetsch R, Reinstein P.

Am Pharm. 1992 Feb;NS32(2):47-9. No abstract available. Erratum in: Am Pharm 1992 Apr;NS32(4):6.

PMID:
1546630
18.

A one-year perspective on MedWatch: the Food and Drug Administration's new medical products reporting program.

Gruchalla RS.

J Allergy Clin Immunol. 1995 Jun;95(6):1153-7. No abstract available.

PMID:
7797782
19.

Vaccine adverse event reporting: the importance of follow-up.

Varricchio F.

Expert Rev Vaccines. 2005 Aug;4(4):445-8. No abstract available.

PMID:
16117700
20.

Adverse drug reactions and reporting.

Witte R.

Clin J Oncol Nurs. 2000 Jul-Aug;4(4):181, 184. No abstract available.

PMID:
11261100

Supplemental Content

Support Center